+22.1%
ALNY vs GSK
+47.2%
-25.1%
-58.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | 0.0% | +0.5% | +0.5% |
| 7D | -6.5% | -3.5% | -3.0% | -5.5% |
| 30D | +11.0% | -3.4% | +14.5% | +12.4% |
| 3M | -14.1% | -8.1% | -5.9% | -11.5% |
| 6M | -22.4% | -11.1% | -11.3% | -19.6% |
| YTD | -37.5% | +0.7% | -38.2% | -37.1% |
| 1Y | -46.9% | +20.1% | -67.1% | -49.0% |
| 3Y | +22.1% | +46.1% | -24.1% | +7.3% |
| All | +22.1% | +47.2% | -25.1% | +7.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling